General Information
An educational meeting series addressing the most controversial areas of current management
Tuesday, October 5, 2010
6:00 pm – 8:30 pm
Course Director:
Jorge Cortes, MD
University of
Texas
M.D. Anderson Cancer Center
Houston, Texas
Venue
Farallon
450 Post Street
San Francisco, California
Phone: 415-956-6998
www.farallonrestaurant.com
Parking
Valet parking is $13 per vehicle. The meeting organizer is not responsible for any parking costs.
Corporate Support
The following company has provided an educational grant in support of this conference:
Continuing Medical Education
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this educational activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is specifically designed for hematologists, oncologists, and other physicians, clinicians, physicians-in-training, and healthcare professionals (oncology nurses, pharmacists, physician assistants) involved and/or interested in the therapeutic management of patients with CML.
Objectives
After successful completion of this course, participants should be able to:
- Identify two practical recommendations for monitoring response and assessing progression in CML patients
- Comment on at least two strategic plans for the management of CML patients who exhibit suboptimal response to treatment.
- Review three second-line therapy options for patients with suboptimal response or who have failed front-line therapy
- Identify two strategic options for choosing front-line CML therapy
Conference Organizer
4325 Alexander Drive
Alpharetta, Georgia
30022-3740, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
www.imedex.com
Faculty
Elias Jabbour, MD
University of Texas
M.D. Anderson Cancer Center
Houston, Texas
Jerald P. Radich, MD
Fred Hutchinson Cancer Research Center
Seattle, Washington
Scientific Agenda
| 6:00 pm | Dinner served |
| 6:30 pm | Welcome and pre-activity knowledge/competence assessment via ARS |
| 6:40 pm | Monitoring response in TKI therapy - Practical recommendations for the practicing hematologist Jerald P. Radich, MD |
| 7:00 pm | Case presentation: Effectively diagnosing and managing suboptimal response Elias Jabbour, MD |
| 7:25 pm | Case presentation: Selecting the optimal second-line therapy for patients with a suboptimal response or who have failed front-line therapy Jerald P. Radich, MD |
| 7:50 pm | Debate: Is it time to move beyond first generation TKIs in frontline therapy of CP-CML? |
| Point: Imatinib is the proven standard of care for nearly all newly diagnosed patients Elias Jabbour, MD |
|
| Counterpoint: It is time to institute frontline therapy with second generation TKIs Jerald P. Radich, MD |
|
| 8:20 pm | Conclusive message and post-activity knowledge/competence assessment via ARS |
| 8:30 pm | Adjourn |
Registration Closed
The Mastering Clinical Challenges in CML meeting schedule for San Francisco on October 5, 2010 is now full. We are no longer accepting registrations for this meeting. If you would like to be added to a waiting list and contacted in the event a space opens up please email meetings@imedex.com with your first and last name as well as an email address or a phone number where you can be reached. Thank you!
